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ABSTRACT
Anticoagulation is needed for stroke prevention
in patients with atrial ﬁbrillation. Antiplatelet
therapy is essential for the prevention of stent
thrombosis and the reduction of cardiovascular
events in patients who undergo coronary
stenting and suffer acute coronary syndromes.
When these conditions overlap, the individual
antithrombotic strategies are commonly
combined, and the efﬁcacy beneﬁt of triple
oral antithrombotic therapy is assumed to
outweigh the bleeding risk based on the
available data. Recent studies have
investigated this topic further, including the
ﬁrst randomized controlled trial to address this
issue. This new evidence challenges previous
assumptions and may have implications for
future practice and investigation.
Keywords: Antiplatelet therapy and
anticoagulation; Coronary stenting and atrial
ﬁbrillation; Triple oral antithrombotic therapy;
Triple therapy; WOEST trial
INTRODUCTION
Of the roughly 15.4 million Americans with
coronary artery disease (CAD), approximately
4.6% of them suffer an acute coronary
syndrome (ACS) each year and 3.2% undergo
percutaneous coronary intervention (PCI) [1].
Of those who undergo PCI, 5–7% have a
preexisting indication for chronic oral
anticoagulation (OAC) [2]. These patients
require antithrombotic strategies that
optimally balance the competing risks of
bleeding, stroke, and stent thrombosis.
Prior to the common use of dual antiplatelet
therapy (DAPT), approximately 6–24% of
patients suffered stent thrombosis in the ﬁrst
year after stent placement, with a mortality rate
up to 50% [3]. With the use of routine DAPT
after PCI, the incidence of stent thrombosis has
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PCI with a mortality rate of 10–20% [2]. OAC is
equally important in atrial ﬁbrillation (AF). The
annual risk of stroke ranges 2–18% depending
on patient risk factors, and warfarin provides a
relative risk reduction of approximately 60%,
versus just 20% for aspirin, as compared to
control [4–6].
There is a paucity of evidence regarding the
optimal antithrombotic strategy for patients on
chronic OAC who undergo PCI. While triple oral
antithrombotic therapy (TOAT) is often
prescribed to maximize reductions of stroke and
stent thrombosis, there is concern that the
increased bleeding risk may outweigh the
assumed efﬁcacy beneﬁt. Until recently, only a
fewformalrecommendationsforantithrombotic
therapies in these patients have been published,
and these recommendations have been based
mostly on retrospective data and older
randomized trials that studied the addition of
warfarin to aspirin in ACS. Based on these data,
current common practice is to use TOAT for at
leastashortperiodoftimeafterPCIdependingon
patient risk factors. Recently, new evidence has
emerged suggesting that other strategies may be
preferred, including a randomized controlled
trial (RCT) to address this topic. This review will
brieﬂy summarize the available evidence and
guidelines and focus on reviewing the newer
studies.
MATERIALS AND METHODS
This review article incorporates data from
observational studies, review articles, available
guidelines, as well as a randomized controlled
trial on the use of TOAT in patients with AF and
CAD. Relevant studies were obtained using a
MEDLINE search for triple antithrombotic
therapy, AF, and PCI. In addition, randomized
controlled trials of the use of anticoagulation
and single antiplatelet therapies (SAPT) in
patients with CAD were also included. Studies
were chosen based on their inclusion and
inﬂuence on current guidelines and practice.
DISCUSSION
Stroke Prevention in AF
AF is a common condition, with a prevalence of
approximately 1% and a lifetime risk of
approximately 25% after the age of 40 [5, 7].
Stroke prevention in AF is one of the most
common indications for chronic OAC, which
has been found to be superior to both single and
dual antiplatelet therapies at reducing stroke [3].
Using the available evidence of the relative
efﬁcacy and safety of warfarin, SAPT with
aspirin, and DAPT with aspirin and clopidogrel,
clinicians are able to tailor stroke prevention
strategies to their individual patients based on
their risk factors. Table 1 depicts the relative
efﬁcacy and safety of these common
antithrombotic strategies in AF, derived from
theAmericanCollegeofChestPhysicians(ACCP)
guidelines for antithrombotic therapy for AF and
based on available data from several studies and
on a number of broad assumptions [3]. For most
patientswithatleastoneriskfactorforstroke,the
efﬁcacy beneﬁt of anticoagulation sufﬁciently
outweighs the bleeding risk and is the most
appropriate choice.
Antiplatelet Therapy After PCI
Antithrombotic therapy is necessary to prevent
recurrent ischemic events and stent thrombosis
after ACS and/or PCI. Aspirin has been long
known to signiﬁcantly reduce cardiovascular
events after ACS [8]. Over the past decade, DAPT
86 Cardiol Ther (2013) 2:85–96
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elective PCI and found to signiﬁcantly
improve outcomes when compared to aspirin
alone, with the majority of studies focusing on
clopidogrel as the second antiplatelet agent [9,
10]. Prasugrel and ticagrelor have been the
subject of more recent investigation; these
agents generally achieve higher degrees of
platelet inhibition than clopidogrel, do not
appear to be affected by CYP2C19
polymorphisms, and have been associated
with reductions in cardiovascular events after
ACS with an associated increase in non-
procedure related bleeding [11, 12].
Current American College of Cardiology
Foundation/American Heart Association/
Society for Cardiovascular Angiography and
Interventions (ACCF/AHA/SCAI) guidelines
recommend at least 12 months of DAPT after
PCI. Several published and ongoing trials have
compared short-term (6–12 months) versus
long-term ([12 months) DAPT after PCI; while
the design and results of these individual trials
can be debated and cross-trial comparisons are
challenging, the overall results suggest a trend
towards a lack of beneﬁt of longer-term DAPT,
regardless of the type of stent used [13–16].
Several ongoing trials are exploring this concept
further; any change in the recommendations
for DAPT duration in the future will have a
notable impact on recommendations for triple
therapy in patients on OAC undergoing PCI.
Anticoagulation After ACS
The use of warfarin after ACS has been studied
in several RCTs and meta-analyses [17, 18]. In
the Warfarin-Aspirin Reinfarction Study
(WARIS II), 3,630 patients with acute
myocardial infarction (MI) were randomized to
either aspirin 160 mg, warfarin with an
international normalized ratio (INR) target of
2.8–4.2, or aspirin 75 mg in combination with
warfarin with an INR target of 2.0–2.5 [19].
When compared to aspirin 160 mg, warfarin
(rate ratio, 0.81; 95% conﬁdence interval [CI],
0.69–0.95; P = 0.03) and warfarin plus aspirin
(rate ratio, 0.71; 95% CI 0.60–0.83; P = 0.001)
produced a signiﬁcant reduction in the
composite primary end point of death, non-
fatal recurrent MI, or thromboembolic stroke.
Both treatments also lead to signiﬁcantly more
major, non-fatal bleeding when compared to
aspirin 160 mg (P\0.001). The two
anticoagulation arms did not differ
signiﬁcantly with respect to either endpoint.
The Anti-thrombotics in the Secondary
Prevention of Events in Coronary Thrombosis-2
(ASPECT-2) trial randomized patients to three
similararmsandshowedsimilarresultstoWARIS
Table 1 Comparison of the efﬁcacy and safety of antithrombotic agents in atrial ﬁbrillation
Death, relative
effect (95% CI)
Non-fatal stroke,
relative effect
(95% CI)
Non-fatal major
extracranial bleeds,
relative effect (95% CI)
Warfarin versus no Tx 0.72 (0.55–0.94) 0.34 (0.23–0.49) 2.58 (1.12–5.97)
ASA versus no Tx 0.89 (0.75–1.05) 0.79 (0.65–0.96) 1.60 (1.40–1.80)
Warfarin versus ASA 0.97 (0.85–1.12) 0.48 (0.33–0.70) 1.42 (0.89–2.29)
Warfarin versus ASA ? clopidogrel 0.98 (0.79–1.22) 0.56 (0.39–0.82) 0.91 (0.67–1.23)
ASA ? clopidogrel versus ASA alone 0.98 (0.90–1.07) 0.72 (0.61–0.85) 1.50 (1.18–1.89)
ASA aspirin, CI conﬁdence interval, Tx treatment
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anticoagulation (hazard ratio [HR], 0.55; 95% CI
0.30–1.00; P = 0.0479) and aspirin plus
moderate-intensity anticoagulation (HR 0.50;
95% CI 0.27–0.92; P = 0.03) lead to a signiﬁcant
reduction in the primary endpoint of death, MI,
or stroke. There was no signiﬁcant difference
between the two anticoagulation groups with
respect to the primary endpoint.
Based on the studies of warfarin in ACS,
driven mostly by the results of WARIS II and
ASPECT-2, warfarin was at least as efﬁcacious as
aspirin at reducing the risk of death, recurrent
MI, and stroke after ACS (Figs. 1, 2)[ 17].
Furthermore, these studies demonstrate that
warfarin alone appears to be sufﬁcient as
single therapy, and the addition of aspirin to
warfarin was not found to have an additional
beneﬁt at reducing the composite endpoint of
recurrent MI, stroke, or death. However,
patients in these studies were not treated with
modern interventional therapies, such as drug-
eluting stents. As such, caution should be taken
in applying these results to current practice.
Evidence and Guidelines for TOAT
A few consensus documents have been
published with recommendations for TOAT,
the bases for which are mostly derived from
small observational studies [3, 21–26]. The
available observational data show that patients
receiving TOAT experienced a roughly threefold
higher risk of major bleeding than did patients
receiving DAPT, while the shorter versus longer
durations of TOAT were associated with a
twofold lower risk of major bleeding [27]. In
patients with previous indications for OAC who
underwent PCI, DAPT with suspension of OAC
was associated with a threefold increased risk of
thromboembolic events, while TOAT was
associated with a lower risk of stent
thrombosis and MI [27]. When analyzed in
aggregate, these studies show that patients with
AF who undergo PCI and suspend OAC during
DAPT suffer an increased incidence of
thromboembolic events when compared to
either TOAT or OAC plus SAPT, while the risk
of major bleeding is increased [27].
Fig. 1 Rate ratios of recurrent myocardial infarction for warfarin plus aspirin compared with aspirin alone. Figure adapted
using data from Rothberg et al. [17]
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Working Group on Thrombosis makes some
recommendations for the management of
patients with AF who have ACS and/or
undergo PCI (Table 2)[ 28]. In general, they
advise not to stop anticoagulation and to use
TOAT for a short period of time after PCI, the
duration of which depends on bleeding risk and
stent type. In addition, they recommended
using bare metal stents, targeting an INR range
2.0–2.5 for patients receiving TOAT, and using
radial access during PCI.
The ACCP published clinical practice
guidelines for the management of
antithrombotic therapy in patients with atrial
ﬁbrillation, including those with AF and CAD
(Table 3)[ 3]. The authors felt that the available
retrospective data were too prone to bias and
instead based their recommendations on the
studies of warfarin in ACS. They made several
assumptions in extrapolating these data,
speciﬁcally that the addition of clopidogrel to
both study arms, aspirin plus warfarin and
aspirin alone, would not change the relative
impacts of those treatments on death, non-fatal
MI, and non-fatal extracranial bleeding. Their
recommendations ultimately differ slightly
from those of the ESC in that they indicate
that OAC can be safely stopped for some
patients at low risk of stroke while on DAPT
after PCI.
Another set of recommendations was
recently published in Circulation:
Cardiovascular Interventions (Fig. 3)[ 2]. For
patients at very low risk of stroke, the authors
advise omitting OAC after PCI. For all other
patients, they recommend TOAT for
1–6 months depending on risks of bleeding
and stent thrombosis and stent type.
Recent Studies
Published in September, 2012, a retrospective
analysis of 11,480 patients in Denmark
registries studied the effect of multiple
antithrombotic strategies used in AF after
Fig. 2 Rate ratios of major bleeding for warfarin plus aspirin compared with aspirin alone. Figure adapted using data from
Rothberg et al. [17]
Cardiol Ther (2013) 2:85–96 89
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123coronary intervention [29]. The authors found
that TOAT was associated with more bleeding
than vitamin k antagonist (VKA) plus SAPT at
90 days (HR 1.47; 95% CI 1.04–2.08) and 1 year
(HR 1.36; 95% CI 0.95–1.95). With regard to
efﬁcacy, TOAT and VKA plus SAPT were
statistically similar (HR 1.15; 95% CI
0.95–1.40) and superior to all other strategies,
suggesting that VKA plus SAPT might be
preferred to TOAT.
Table 3 ACCP guidelines
Stroke risk Clinical setting Type of stent Recommendation
CHADS2 0–1 Elective or ACS BMS or DES 0–12 mos: DAPT
After 12 mos: OAC
CHADS2[1 Elective BMS 0–1 mo: TOAT
1–12 mos: OAC ? SAPT
After 12 mos: OAC
DES 0–6 mos: TOAT
6–12 mos: OAC ? SAPT
After 12 mos: OAC
ACCP guidelines for the management of antithrombotic therapy in patients with atrial ﬁbrillation after coronary stenting
ACCP American College of Chest Physicians, BMS bare metal stent, DES drug-eluting stent, mos months, OAC oral
anticoagulant, SAPT single antiplatelet therapy, TOAT triple oral antithrombotic therapy
Fig. 3 Circulation guidelines for the management of
antithrombotic therapy in patients with atrial ﬁbrillation
after coronary stent placement. Asterisk In patients at high
risk for atherothrombotic events including stent thrombo-
sis, continued single antiplatelet therapy with warfarin
should be considered after 12 months. BMS bare metal
stent, DES drug-eluting stent, mos months, OAC oral
anticoagulation, SAPT single antiplatelet therapy, TOAT
triple oral antithrombotic therapy
Cardiol Ther (2013) 2:85–96 91
123The What is the Optimal antiplatElet and
anticoagulant therapy in patients with oral
anticoagulation and coronary StenTing
(WOEST) trial is a completed RCT to study the
comparison of TOAT versus VKA plus SAPT [30].
The trial design and rationale were published in
2009, and the study was published in February,
2013 [30–32]. The authors randomized 573
patients undergoing PCI in an open-label,
intention-to-treat design to either double
therapy (warfarin and clopidogrel 75 mg) or
triple therapy (warfarin, clopidogrel 75 mg, and
aspirin80 mg)inordertotestthehypothesisthat
double therapy is superior to triple therapy with
respect to bleeding. Study patients were free of
anythrombolysisinmyocardialinfarction(TIMI)
major bleeding in the past 1 year and had an
indication for OAC for at least 1 year after PCI.
Approximately,70%ofpatientsrequiredOACfor
AF; mechanical valves accounted for
approximately 10%. The primary endpoint was
thecompositeofallTIMIbleeding;thesecondary
endpoints included the composite of death, MI,
stroke, systemic embolism, target vessel
revascularization and stent thrombosis, as well
as the individual components of the composite
endpoints.
At1 year,thecumulativeincidenceofallTIMI
bleeding, which included major, minor, and
minimal events, was 44.4% in the triple therapy
group compared to 19.4% with double therapy
(HR 0.36; 95% CI 0.26–0.50; P\0.0001). The
results were driven by differences in TIMI
minimal and minor bleeding, with a non-
signiﬁcant trend towards a reduction in TIMI
major bleeding seen with double therapy. There
was no difference in intracranial bleeding
between the two groups. The primary endpoint
differences were consistent across old age,
gender, ACS, indication for OAC, and stent type.
The composite of death, MI, stroke, systemic
embolism, target vessel revascularization, and
stent thrombosis occurred in 17.6% of patients
receiving triple therapy compared to 11.1%
receiving double therapy (HR 0.56; 95% CI
0.35–0.91; P = 0.025). This difference was
driven by a reduction in all-cause mortality,
with one-year rates of 6.3% versus 2.5% in triple
and double therapy, respectively (HR 0.39; 95%
CI 0.16–0.93; P = 0.027). Rates of MI, stroke,
and stent thrombosis were numerically lower in
the double therapy group without statistical
signiﬁcance.
Integrating New Data into Practice
As previously discussed, several of the trials that
studied the use of warfarin in ACS, such as
WARIS II and ASPECT-2, included arms that
compared warfarin alone versus warfarin plus
aspirin and found no statistically signiﬁcant
difference in efﬁcacy [17]. These results set a
precedent to suggest that the addition of aspirin
to therapeutic anticoagulation does not add
signiﬁcantly to the prevention of death, non-
fatal MI, or stroke after ACS; however, notably,
there were low rates of coronary interventions.
The results of the recent Denmark registry study
discussed above suggests that triple therapy
provides no additional efﬁcacy beneﬁt while
increasing bleeding when compared to VKA
plus SAPT [29]. The WOEST trial results suggest
that in patients on chronic OAC undergoing
PCI, double therapy with warfarin and
clopidogrel could be a preferred strategy with
respect to mortality and bleeding when
compared to TOAT with warfarin, clopidogrel,
and aspirin. Thus, the WOEST results contribute
further to the concept that OAC plus SAPT
might be preferable to TOAT in patients with AF
after PCI.
In WOEST, the increase in non-major TIMI
bleeding seen with triple therapy was driven
largely by gastrointestinal bleeding, skin
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sites. Notably, proton pump inhibitors (PPIs)
were used in just 25–27% of patients, and radial
access during PCI was performed in only
34–39%; the authors did not encourage the
use of PPIs or radial access in an effort to
reproduce a more generalizable study
population. The reduction in bleeding seen
with double therapy was isolated to TIMI
minimal and minor bleeding. However, as the
authors mention, non-major bleeding episodes
are clinically relevant and often lead to further
complications, such as the thrombotic
consequences of stopping antithrombotic
therapy in response to bleeding.
The WOEST authors chose to exclude aspirin
rather than clopidogrel in the double therapy
group due to concern that stent thrombosis may
be unacceptably increased when dropping
clopidogrel. The Denmark registry study
grouped VKA plus SAPT in the analysis without
differentiating the choice of SAPT, but did note
that an analysis of the subset of patients who
received VKA plus clopidogrel yielded a bleeding
risk similar to that with triple therapy. As such,
there is uncertainty regarding the ideal single
antiplatelet agent and further investigation is
needed before declaring one strategy superior to
another. To that end, a trial of patients withOAC
undergoing PCI that includes arms of warfarin
plus clopidogrel and warfarin plus aspirin would
be useful. Prasugrel and ticagrelor also deserve
mention in this setting; while the increase in
bleeding associated with these agents raises
concern for their use in triple therapy, it would
beinformativetostudytheirefﬁcacyaspartofan
OAC plus SAPT regimen in this patient
population.
Caution is warranted in interpreting the
WOEST efﬁcacy results; the study was designed
to evaluate safety, not efﬁcacy, and while the
composite secondary endpoint met statistical
signiﬁcance, the individual components of MI,
stroke,andstentthrombosisdidnot.Theconcept
of dual therapy actually reducing ischemic and
thrombotic events, such as stent thrombosis, is
contrary to prior data; given the relatively small
study population, such a conclusion should be
supported by additional data.
For now, the approaches outlined by the ESC,
ACCP, and Circulation authors offer guidance
regarding TOAT, and the ﬂow diagram in Fig. 3
above provides an approach to choose
antithrombotic therapies. Based on the WOEST
results, for the subset of patients at moderate to
high risk of stroke, high risk of bleeding, and low
risk of stent thrombosis, in whom the Circulation
authors, for example, currently recommend one
month of TOAT followed by 11 months of VKA
plus SAPT, VKA plus SAPT for all 12 months may
be a reasonable alternative. However, additional
studies are needed to substantiate this approach.
For patients at high risk of stent thrombosis, the
WOEST trial does not adequately quell concerns
that the risk of stent thrombosis will not be
unacceptably high if one antiplatelet agent is
dropped, and in these patients, a short period of
TOAT is probably still reasonable. Regardless of
the pharmacological approach, these patients at
high risk of both stroke and stent thrombosis
should receive bare metal stents whenever
feasible.
Lastly, the role of newer anticoagulant
agents in TOAT deserves mention, although a
full discussion of this topic is beyond the scope
of this paper. Dabigatran, rivaroxaban, and
apixaban are the three new FDA-approved
agents for stroke prevention in non-valvular
atrial ﬁbrillation, and these agents were shown
to have favorable safety proﬁles when compared
to warfarin, all leading to signiﬁcant reductions
in hemorrhagic stroke [33–35]. These agents, in
varying doses, have been studied in ACS
patients treated with background dual
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trials did not have an indication for chronic
full-dose OAC (e.g., AF) [36–39]. As such, further
investigation is needed to determine what role
these agents may play in TOAT.
CONCLUSION
Patients on chronic OAC who undergo PCI
challenge clinicians to choose the
antithrombotic strategy that best balances
their unique set of competing risks. Only a few
formal recommendations have been published
on this issue and all advise using TOAT in some
patients for 1–6 months after PCI in an effort to
maximize reductions of stroke and stent
thrombosis. Based on available data, TOAT is
assumed to provide an efﬁcacy beneﬁt that is
superior to dual therapy and that sufﬁciently
outweighs any increased bleeding risk of TOAT.
The WOEST trial was a RCT designed to
address this issue. The results provide new
groundwork for the assumption that triple
therapy does yield more bleeding, while
challenging prior assumptions of the efﬁcacy
beneﬁt of TOAT. As discussed, caution should
be taken with this data, awaiting further studies
prior to changing practice, and only applying
the results to the proper population. In time,
these results may impact clinical practice and
set the stage for further trials in this area.
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